$69 postpage LB

Prescient’s Clinical Trials for PTX-100 Continues to Next Dose Level

  • April 22, 2020 12:33 PM AEST
  • Team Kalkine

A clinical-stage Oncology company Prescient Therapeutics Limited (ASX:PTX) revealed that its phase 1b study of PTX-100 for cancer will move to the next dose level of 1,000 mg/m2 after half that amount was demonstrated safe in the first cohort of patients.

Gold MTF non-AMP

The Study now expands to Australia, to include PASO in South-Eastern Victoria under the guidance of Professor Vinod Ganju.

PTX-100 is being tested against several tumors, as it is not targeting tumour origin but two specific genetic mutations (Ras and RhoA).

The share price of PTX climbed by 11.429% to $0.039 at AEST 12:02 PM.


The website https://kalkinemedia.com/au is a service of Kalkine Media Pty. Ltd. (Kalkine Media) A.C.N. 629 651 672. The principal purpose of the content on this website is to provide factual information only and does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stock of the company (or companies) or engage in any investment activity under discussion. We are neither licensed nor qualified to provide investment advice through this platform. In providing you with the content on this website, we have not considered your objectives, financial situation or needs. You should make your own enquiries and obtain your own independent advice prior to making any financial decisions.
Some of the images that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed on this website unless stated otherwise. The images that may be used on this website are taken from various sources on the web and are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it below the image. The information provided on the website is in good faith, however Kalkine Media does not make any representation or warranty regarding the content, accuracy, or use of the content on the website.


We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK